Effectiveness of High-Frequency Repetitive Transcranial Magnetic Stimulation in Patients With Spinocerebellar Ataxia Type 3 : The Journal of ECT

Secondary Logo

Journal Logo

Original Study

Effectiveness of High-Frequency Repetitive Transcranial Magnetic Stimulation in Patients With Spinocerebellar Ataxia Type 3

Zhou, Menglu MD*; Qiu, Mengqiu MD†; Jin, Yi MD‡; Li, Dan MD§; Tao, Chenjuan MD*; Lou, Danning MD*; Hu, Zhouyao MD‡; Wang, Yuchen MD‡; You, Zhiyuan MD‡; Shao, Yimeng MD‡; Zhu, Yingying MD‡; Qu, Mingyue MD‡; Lu, Xiaodong MD, PhD*

Author Information
The Journal of ECT ():10.1097/YCT.0000000000000925, April 24, 2023. | DOI: 10.1097/YCT.0000000000000925

Abstract

Objective 

To investigate the effectiveness of high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) on improvement of clinical symptoms in patients with spinocerebellar ataxia type 3 (SCA3).

Methods 

Sixteen SCA3 participants diagnosed by genetic testing were enrolled in this sham-controlled and double-blind trial. They received either a 2-week 10-Hz rTMS intervention or sham stimulation targeting the vermis and cerebellum. The Scale for Assessment and Rating of Ataxia and the International Cooperative Ataxia Rating Scale were completed at baseline and poststimulation.

Results 

Compared with baseline, the HF-rTMS group demonstrated a significant improvement in the total Scale for Assessment and Rating of Ataxia (P < 0.0001) and the International Cooperative Ataxia Rating Scale scores (P = 0.002). After 2-week treatment, the real group exhibited decreasing pattern in 3 subgroups, especially for limb kinetic function (P < 0.0001).

Conclusions 

Short-term HF-rTMS treatment is a potentially promising and feasible tool for rehabilitation in patients with SCA3. Studies with long-term follow-up need to be carried out in the future and further need to assess gait, limb kinetic function, speech and oculomotor disorders.

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid